PTGER1 and arthritic joint disease: In 2002, McCoy and their groups showed that prostaglandin EP4 receptor, but not EP1, EP2, EP3 receptor-deficient mice decreased the incidence and severity of disease in the mouse arthritis model, suggesting that the mimotope of the prostaglandin EP4 receptor might provide novel agents for the treatment of rheumatoid arthritis [2].